These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 28916388)

  • 1. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro.
    Reich M; Deutschmann K; Sommerfeld A; Klindt C; Kluge S; Kubitz R; Ullmer C; Knoefel WT; Herebian D; Mayatepek E; Häussinger D; Keitel V
    Gut; 2016 Mar; 65(3):487-501. PubMed ID: 26420419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
    J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid receptors in the biliary tree: TGR5 in physiology and disease.
    Deutschmann K; Reich M; Klindt C; Dröge C; Spomer L; Häussinger D; Keitel V
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1319-1325. PubMed ID: 28844960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
    Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
    Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of bile acid receptor agonists in pulmonary disease models.
    Comeglio P; Morelli A; Adorini L; Maggi M; Vignozzi L
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1215-1228. PubMed ID: 28949776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
    Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
    Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile Acid G Protein-Coupled Membrane Receptor TGR5 Modulates Aquaporin 2-Mediated Water Homeostasis.
    Li S; Qiu M; Kong Y; Zhao X; Choi HJ; Reich M; Bunkelman BH; Liu Q; Hu S; Han M; Xie H; Rosenberg AZ; Keitel V; Kwon TH; Levi M; Li C; Wang W
    J Am Soc Nephrol; 2018 Nov; 29(11):2658-2670. PubMed ID: 30305310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
    Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
    J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
    Ito K; Okumura A; Takeuchi JS; Watashi K; Inoue R; Yamauchi T; Sakamoto K; Yamashita Y; Iguchi Y; Une M; Wakita T; Umezawa K; Yoneda M
    Hepatology; 2021 Jul; 74(1):83-98. PubMed ID: 33434356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
    Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
    Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development.
    Lozano E; Sanchez-Vicente L; Monte MJ; Herraez E; Briz O; Banales JM; Marin JJ; Macias RI
    Mol Cancer Res; 2014 Jan; 12(1):91-100. PubMed ID: 24255171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGR5 promotes cholangiocarcinoma by interacting with mortalin.
    Li AD; Xie XL; Qi W; Wang WB; Ma JJ; Zhao DQ; Jiang XY; Chen L; Bai Y; Jiang HQ
    Exp Cell Res; 2020 Apr; 389(2):111855. PubMed ID: 31978385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile acid receptor TGR5 overexpression is associated with decreased intestinal mucosal injury and epithelial cell proliferation in obstructive jaundice.
    Ji CG; Xie XL; Yin J; Qi W; Chen L; Bai Y; Wang N; Zhao DQ; Jiang XY; Jiang HQ
    Transl Res; 2017 Apr; 182():88-102. PubMed ID: 28034761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.
    Baghdasaryan A; Claudel T; Gumhold J; Silbert D; Adorini L; Roda A; Vecchiotti S; Gonzalez FJ; Schoonjans K; Strazzabosco M; Fickert P; Trauner M
    Hepatology; 2011 Oct; 54(4):1303-12. PubMed ID: 22006858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.